newsfilter
← Latest News
GlobeNewswire·

NervGen Pharma Begins Trading on Nasdaq Today

  • NervGen Pharma common shares were approved for listing on Nasdaq & began trading today under the symbol "NGEN".
  • The listing follows expanded Phase 1b/2a CONNECT SCI data showing durable functional & quality-of-life improvements in chronic spinal cord injury patients.
  • NVG-291 demonstrated statistically significant improvements in upper-limb corticospinal signaling & reductions in reticulospinal signaling.
  • NervGen plans to conduct an FDA End-of-Phase 2 meeting in early 2026 to align on the development & registration pathway for NVG-291.
  • An FDA Type C meeting in September 2025 confirmed multiple regulatory pathways are available to support approval.
  • Enrollment for subacute spinal cord injury patients in the CONNECT SCI Study is ongoing alongside preparations for a Phase 3 trial.
  • NVG-291 holds Fast Track designation from the FDA & Orphan Drug designation from the European Medicines Agency.
  • The company is pursuing a pharmacologic approach to transform treatment paradigms for neurotraumatic & neurologic conditions using NVG-291 & the next-generation candidate NVG-300.